Share-based Payment Arrangement, Expense of SAB Biotherapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SAB Biotherapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
  • SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $3,169,734, a 370% increase year-over-year.
  • SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $5,210,647, a 77% increase year-over-year.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $5,210,647, a 77% increase from 2024.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,941,796, a 21% increase from 2023.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,423,720, a 9.4% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

SAB Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $5,210,647 $3,169,734 +$2,495,599 +370% 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $2,715,048 $800,764 -$248,019 -24% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $2,963,067 $627,198 +$25,765 +4.3% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $2,937,302 $612,951 -$4,494 -0.73% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $2,941,796 $674,135 +$137,256 +26% 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $2,804,540 $1,048,783 +$409,537 +64% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $2,395,003 $601,433 -$43,382 -6.7% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $2,438,385 $617,445 +$14,665 +2.4% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $2,423,720 $536,879 -$91,661 -15% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $2,515,381 $639,246 +$61,043 +11% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $2,454,338 $644,815 +$74,954 +13% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $2,379,384 $602,780 -$294,820 -33% 01 Jan 2023 31 Mar 2023 10-Q 20 May 2024 2024 Q1
Q4 2022 $2,674,204 $628,540 -$22,932 -3.5% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $2,697,136 $578,203 -$302,461 -34% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,999,597 $569,861 +$136,430 +31% 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023 2023 Q2
Q1 2022 $2,863,167 $897,600 +$548,485 +157% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $2,314,682 $651,472 01 Oct 2021 31 Dec 2021 10-K/A 28 Apr 2023 2021 FY
Q3 2021 $880,664 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $433,431 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $349,115 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

SAB Biotherapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $5,210,647 +$2,268,851 +77% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $2,941,796 +$518,076 +21% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $2,423,720 -$250,484 -9.4% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $2,674,204 +$359,522 +16% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $2,314,682 +$1,019,259 +79% 01 Jan 2021 31 Dec 2021 10-K/A 28 Apr 2023 2021 FY
2020 $1,295,423 01 Jan 2020 31 Dec 2020 10-K/A 28 Apr 2023 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.